

NEWS RELEASE

FOR IMMEDIATE RELEASE

Protea Presents New Technology at Pittcon Conference & Expo

New chip technology provides rapid and sensitive quantitation of small molecules

New Orleans, LA; 8:00 AM ET, March 9th 2015 – Protea Biosciences Group, Inc. (OTCQB: PRGB) ("Protea") announced today that it is presenting a new chip-based technology at the Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy (Pittcon), held in New Orleans, LA. This nanopost array technology, called REDIchip™ (Resonance-Enhanced Desorption Ionization), was invented in the laboratory of Akos Vertes, PhD., Department of Chemistry, The George Washington University. The chip is designed to be used for mass spectrometric analysis on MALDI platforms without the need for matrix.

"REDIchips provide a solution to pharmaceutical researchers interested in detecting small molecules without the common interference of chemical matrix. The ability to reproducibly detect and quantitate small molecules is made possible due to the structured nanopost array (NAPA) present in the silicon chip," stated Haddon Goodman, Imaging Program Manager. He continued, "The REDIchip enables more sensitive quantitation for small molecules than traditional workflows using a robust and reproducible matrix-free environment."

Protea's REDIchip technology figures of merit are being presented today at the Pittcon conference, and the commercial product is expected to be available at the upcoming American Society for Mass Spectrometry (ASMS) conference Spring 2015. The commercial product will be compatible with a variety of MALDI systems, and it will allow rapid and reproducible sample analysis of small molecules by laser desorption ionization.

About Protea Biosciences Group, Inc.

Protea Biosciences Group, Inc. (OTCQB:PRGB) is a molecular information company providing innovative bioanalytical solutions to the pharmaceutical and life science industries. "Molecular information" refers to the generation and bioinformatic processing of very large data sets, obtained by applying the Company's technology to identify and characterize the proteins, metabolites, lipids and other biomolecules which are the byproducts of all living cells and life forms.

The Company is applying its technology to the development of next generation, "direct molecular imaging" technology and service capabilities that enable more rapid and comprehensive molecular profiling of human disease.

Forward-Looking Statements



Protea Biosciences Group, Inc.
955 Hartman Run Road
Morgantown, WV 26507
P: 304.292.2226
F: 304.292.7101
www.proteabio.com

This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

For more Information:

Protea Biosciences Group, Inc., 955 Hartman Run Road, Morgantown, WV 26505 USA
Phone: 304.292.2226 Fax: 304.292.7101
haddon.goodman@proteabio.com

<https://proteabio.com/investors>

Protea and LAESI are registered trademarks of Protea Biosciences Group, Inc.